Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for rhinitis and preparation method thereof

A composition and drug technology, applied in the direction of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the problems of long taking cycle, heavy dose burden of rhinitis population, slow onset of effect, etc., to achieve fast onset of effect and shorten treatment time, effect of dose reduction

Pending Publication Date: 2022-05-27
苑立超
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] But existing roxithromycin medicine is basically the preparation of oral administration, comprises tablet, dispersible tablet, granule, capsule, soft capsule etc., is clinically applied to rhinitis single dosage and is 150mg, and daily dose 300mg, dosage partial Large, long taking cycle, all are administered orally, and the onset speed is slow
The dose burden of rhinitis group is relatively heavy, and the existing preparations cannot give full play to the advantages of low dose, long-term application and anti-inflammation of roxithromycin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for rhinitis and preparation method thereof
  • Pharmaceutical composition for rhinitis and preparation method thereof
  • Pharmaceutical composition for rhinitis and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] First, 300 mg of roxithromycin raw material was made into micropowder A for standby use, 9000 mg of microcrystalline cellulose and 1000 mg of sodium carboxymethyl cellulose were dissolved in 300 ml of purified water for high-speed homogenization to obtain B for standby use, and 6 ml of glycerol was dissolved in 200 ml of purified water. Stir well to obtain solution 1; add 10 g of glucose and 5 mg of disodium EDTA to 100 ml of purified water and dissolve to obtain solution 2; add solution 1 to solution 2 with stirring, add A and B respectively to homogenize, and make up the purified water to 1000 ml. quality, adjust the pH to 7.0, and homogenize into 100 cans.

Embodiment 2

[0026] Embodiment 2, first make 200mg of roxithromycin raw material into micropowder A for standby use, dissolve 6000mg microcrystalline cellulose and 700mg sodium carboxymethyl cellulose in 200ml purified water, and obtain B by high-speed homogenization, and dissolve 50ml glycerol in 600ml In purified water, stir well to obtain solution 1; add 5 mg of disodium EDTA and 15 g of glucose into 100 ml of purified water, and dissolve to obtain solution 2; stir solution 1 into solution 2, add A and B respectively to homogenize, and make up for purified water To 1000ml, homogenize, adjust pH to 7.1, and homogenize into 100 cans.

Embodiment 3

[0027] Embodiment 3, first make roxithromycin raw material 400mg into micropowder A for standby use, dissolve 2000mg microcrystalline cellulose and 2400mg sodium carboxymethyl cellulose in 200ml purified water to obtain B by high-speed homogenization, and dissolve 10ml glycerol in 200ml In purified water, stir well to obtain solution 1; add 0.1 mg of disodium EDTA and 10 g of glucose into 200 ml of purified water, and dissolve to obtain solution 2; stir solution 1 into solution 2, add A and B respectively and homogenize to supplement the purification Water to 1000ml, homogenize, adjust pH to 6.9, and homogenize into 100 cans.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines for treating nasal diseases, in particular to a pharmaceutical composition for treating rhinitis and a preparation method thereof.The pharmaceutical composition for treating rhinitis comprises one or more of roxithromycin, microcrystalline cellulose, sodium carboxymethyl cellulose, Tween 80, EDTA disodium, glucose, glycerin, purified water and a PH regulator. The pharmaceutical composition for rhinitis can be prepared into nasal drops or nasal spray.

Description

technical field [0001] The invention relates to the technical field of medicine for treating nasal diseases, in particular to a pharmaceutical composition for treating rhinitis and a preparation method thereof. Background technique [0002] Roxithromycin is a macrolide drug, which is a broad-spectrum antibiotic, especially for Gram-positive bacteria, anaerobic bacteria, chlamydia and mycoplasma and other pathogens, and the main pathogenic bacteria of chronic rhinitis are Blue-positive bacteria, so giving roxithromycin can achieve effective antibacterial effect. According to literature reports, the antibacterial range of roxithromycin is similar to that of erythromycin, and its antibacterial activity is 1 to 5 times higher than that of erythromycin, so that the bactericidal activity is stronger. Facilitates the efflux of nasal secretions, thereby relieving respiratory symptoms. According to reports in the literature, the drug did not accumulate in the human body when the dr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/08A61K9/12A61K31/7048A61K47/38A61P11/02A61P31/02A61P31/04
CPCA61K31/7048A61K9/08A61K9/0043A61K9/12A61K47/38A61P11/02A61P31/04A61P31/02Y02A50/30
Inventor 苑立超
Owner 苑立超
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com